Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer’s trials
Deena Beasley SAN DIEGO, Dec 2 (Reuters) – Novo Nordisk launched a pivotal trial of its GLP-1 drug semaglutide in Alzheimer’s patients in 2020 based on findings from human, animal and real-world studies, a Novo Nordisk executive said on Tuesday, acknowledging criticism that the Novo Nordisk study had design flaws. Although the trials failed to…